Compal showcases quantum-AI hybrid platform for drug discovery at COMPUTEX 2026, achieving up to 3,500× speed-ups over traditional molecular docking methods.

Compal Electronics demonstrated CGA-QX Docking, a production-ready platform developed with NVIDIA and academic partners under NSTC funding, combining NVIDIA CUDA-Q quantum simulations with GPU-accelerated simulated annealing to achieve up to 3,500× speed-ups over traditional molecular docking methods.

The platform uses 30-qubit quantum optimization to improve binding-energy prediction accuracy for targets like Alzheimer's disease, and integrates generative AI for antibody drug development in partnership with the College of Pharmaceutical Sciences at National Yang Ming Chiao Tung University (NYCU), employing fine-tuned ESM-2 protein language models for specificity prediction.

The molecular docking system has been validated through practical testing with Kaohsiung Medical University and leverages quantum algorithms to optimize molecular configuration searches across millions of potential binding sites.